Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- KM Biologics Begins Formulation of AstraZeneca’s COVID-19 Vaccine
March 22, 2021
- Takeda’s OTC Unit to Be Renamed Alinamin with New Chief from Blackstone
March 22, 2021
- Nippon Shinyaku Gets Japan Rights to Menarini’s Blood Cancer Med
March 19, 2021
- Takeda Rolls Out Music App to Encourage Exercise for Parkinson’s Patients
March 18, 2021
- PII Study Now underway for StemRIM’s Redasemtide for Chronic Liver Disease
March 18, 2021
- Medicago/GSK Begins PIII for COVID-19 Vaccine, Mitsubishi Mum on Japan Plan
March 18, 2021
- Eisai, German Institute Link Arms on Neurodegenerative Disorder Research
March 18, 2021
- Torii Gets Japan Rights to Verrica’s Wart Drug
March 18, 2021
- Shionogi Curbing Supplies of Claritin Dry Syrup after Alesion Recalls
March 18, 2021
- Sawai Reaches Settlement over Doping Substance Contamination Lawsuit
March 18, 2021
- Fujifilm Invests 100 Million Yen in Cell Therapy Startup Cuorips
March 17, 2021
- Eisai’s Anti-Tau Antibody Picked for US Prevention Trial for Inherited Alzheimer’s
March 17, 2021
- CureApp Hypertension Therapeutic App Hits PIII Goal, 2021 Submission Eyed
March 17, 2021
- Morimoto Pharma Looking to Partner with Drug Makers, CMOs to Develop Freeze-Dried COVID Vaccines in Japan
March 17, 2021
- Otsuka Grabs Japan Rights to Perception’s Antidepressant
March 17, 2021
- Nippon Shinyaku Taps Global-Savvy Toru Nakai as New President
March 17, 2021
- Takeda Pitches In Production Capacities for J&J’s COVID-19 Vaccine
March 17, 2021
- Quake-Halted Nipro Plant Affecting Supplies of Pfizer, Espha Generics
March 17, 2021
- Alesion Dry Syrup, Generics Pulled from Shelves over Mutagenic Impurities
March 16, 2021
- Novartis, Meiji to End Copromotion for Ultibro, Seebri
March 16, 2021
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…